Abbott to Streamline Dx Business, Cut Jobs | GenomeWeb
This article has been updated from a previous version to correct the amount of GE's offer for Abbott.
 
NEW YORK (GenomeWeb News) – Abbott Laboratories disclosed in a filing with the US Securities and Exchange Commission today that it would cut costs in its global diagnostics business through a plan expected to yield annual pre-tax savings of more than $150 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.